PLDN expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 2.90909996092381E-09 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.00989999995971E-06 |
Normal-vs-Stage2 |
7.849600E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
7.918200E-03 |
Stage1-vs-Stage2 |
5.368200E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
9.292400E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
5.565200E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
1.81770000162729E-08 |
Normal-vs-AfricanAmerican |
1.850440E-01 |
Normal-vs-Asian |
2.174400E-04 |
Caucasian-vs-AfricanAmerican |
8.385000E-04 |
Caucasian-vs-Asian |
6.128800E-01 |
AfricanAmerican-vs-Asian |
1.175980E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
3.59050000000583E-05 |
Normal-vs-Female |
9.78139999996408E-07 |
Male-vs-Female |
2.615400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
2.498600E-03 |
Normal-vs-Extreme_Weight |
1.62957999999547E-05 |
Normal-vs-Obese |
7.595500E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
2.672800E-01 |
Normal_Weight-vs-Obese |
1.349210E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
6.125200E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
2.261600E-01 |
Normal-vs-Age(41-60Yrs) |
4.589800E-04 |
Normal-vs-Age(61-80Yrs) |
3.54599999996541E-06 |
Normal-vs-Age(81-100Yrs) |
3.511600E-02 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.945000E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.834010E-02 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.583000E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.911000E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.782400E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.333600E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
4.928400E-01 |
Normal-vs-Grade 3 |
2.621600E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
8.259800E-01 |
Grade 2-vs-Grade 4 |
4.928400E-01 |
Grade 3-vs-Grade 4 |
2.621600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
2.85260004506682E-09 |
Normal-vs-N1 |
1.333560E-02 |
N0-vs-N1 |
1.554820E-01 |
|
|